|
|
| For most cancers, the majority of physicians and researchers have agreed on a "standard treatment approach" - the way in which cancer should be treated based on years of systematic study and research. Clinical trials involve research with new treatments and with new ways of using standard treatments. In general, these trials test the effectiveness of a new treatment, usually in comparison with the best available standard treatment. If a treatment has not been accepted as one of the standard treatments, it is called experimental or investigational. Because of the experimental nature of the treatment, participating patients are monitored very carefully for side effects as well as for benefits. A patient must give informed consent to participate in such research before any treatment is administered. You may want to participate in a clinical trial for several reasons. It may give you the opportunity to receive treatment that is more effective or less toxic than the standard treatment. You may also be able to gain access to a new drug that is not generally available. In addition, your participation in this research effort leads to a more rapid accumulation of knowledge that may help others. The clinical trial process is a prerequisite for making progress in cancer treatment. HemOnCare offers participation in many clinical trials through its collaboration with national cooperative groups, local universities, and pharmaceutical companies. Lois Helgesen our Clinical Research Coordinator , Dr. Ahmed our principal investigator, or any of our physicians will gladly answer questions regarding our clinical trials. Additionally we have information about and access to many other trial sites. Please feel free to discuss any questions or interests you may have with us. The National Cancer Institute maintains a clinical trials information resource at http://cancertrials.nci.nih.gov. The studies in which we are currently participating as investigators are listed below. LUNG CANCER Phase III, Randomized,
Double Blind, Multi-Center Study Of The Efficacy Of Taxotere In Combination With
A Cox-2 Inhibitor Versus Taxotere And Placebo In Non Small Cell Lung Cancer
Patients After Failure Of Prior Platinum-Based Chemotherapy. Randomized, Phase III
Trial Comparing CPT-11/Cisplatin With Etopside/Cisplatin In Patients With
Previously Untreated, Extensive, Small-Cell Lung Cancer. BREAST CANCER A Randomized Open-Label,
Multicenter Study To Evaluate The Use Of Zoledronic Acid In The Prevention Of
Cancer Treatment-Related Bone Loss In Postmenopausal Women With ER+ And/Or PR+
Breast Cancer Receiving Letrozole As Adjuvant Therapy. Randomized, Study Of
Epirubicin/Cyclophophamide Followed By Taxane (Sequential Therapy) Versus
Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Node
Positive Breast Cancer. OVARIAN CANCER Interferon Gamma 1b In
Combination With Chemotherapy For First-Line Therapy Of Advanced Ovarian Or
Primary Peritoneal Carcinoma. A Phase II Study Of Xeloda
In Combination With Intravenous CPT-11 For Patients With Locally Advanced And Or
Metastatic Colorectal Cancer. PROSTATE
CANCER Investigational Drug
Versus Placebo In Non-Metastatic Hormone Refractory Prostate Cancer. CLL Randomized Study Of
Fludarabine And Cyclophosphamide With Or Without Genasense In Patients With
Relapsed Or Refractory Chronic Lymphocytic Leukemia. MULTIPLE MYELOMA Randomized Phase III Study Of Dexamethasone With Or Without Bcl-2 Antisense Oligonucleotide In Patients With Relapsed Or Refractory Multiple Myeloma. NON-HODGKINS
LYMPHOMA Phase III Comparative
Trial Of Investigational Medication +Rituximab In The Treatment Of Patients With
Relapsed Or Refractory Indolent NHL. Open Label Phase II Multi
Center Trial Of An Investigational Medication In Patients With Aggressive
Refractory NHL. CANCER CACHEXIA Phase III Double Blind
Randomized Placebo Controlled Dose Titration Study Of Imidapril Hydrochloride In
The Treatment Of Cancer Cachexia.
|
|
DISCLAIMER: The HemOnCare Online website is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided at the website should not be used for diagnosing or treating a health problem or disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition, including concerns you may have related to chemotherapy, radiation therapy, or other cancer therapies should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider. Send mail to akiva@hemoncare.com
with questions or comments about this web site.
|